Other biomarkers currently available for monitoring patient responses to immunotherapy include the tumor mutation burden (TMB),8 target gene mutations (KRAS, EGFR, ALK, etc.),9 and circulating tumor genes (ctDNA).10 Here, ALK is linked to neoplasm.